HOYA Vision Care Releases Results of Study on MiYOSMART  Chameleon Spectacle Lens Wearers 


Valuable insight gained from patient dataafter the first year of the sun solution rollout  

HOYA Vision Care, a leader in optical technology innovation, today  released results of the Early Experience Program (EEP) research focusing on the experience of patients  after wearing MiYOSMART sun solution Chameleon lenses. The photochromic lenses, released in  April 2023, provide an all in-one solution to myopia management and protected outdoor activity by  rapidly adapting to the level of sunlight, fading back to clear indoors in seconds. 

The goal of the Early Experience Program was to evaluate the acceptance of MiYOSMART Chameleon  spectacle lenses, as well as gain insights into the wearers’ habits. HOYA Vision Care proactively  collected and analyzed data from 100 patients, aged 3 to 20 years old, located across Europe, Asia,  Australia, and New Zealand1. The results of the EEP showed that the MiYOSMART Chameleon  spectacle lenses allowed rapid adaptation, with almost 80% (n=65) of patients adapting within one day  to their new lenses2. Of note, teenagers adapted to the new lenses as quickly as younger children3.  Additionally, 100% (n=65) of Chameleon spectacle wearers, both new wearers and experienced  wearers, were satisfied with their visual performance during both outdoor and indoor activities and were  comfortable with the fade back to clear, regardless of geographic location.4  

“The results of our Early Experience Program, showing great adaptation, tolerability and overall  satisfaction in patients of different ages and ethnicities is testament to HOYA’s research and  commitment to providing innovative solutions.” “The findings around photophobia and increased  wearing time, highlight the potential of MiYOSMART Chameleon lenses to improve the outcomes of  myopia management in children, while being comfortable and retaining good visual performance,” said  Marianne Goldwaser, Professional Affairs Manager at HOYA Vision Care. “We will continue touching